Precision BioSciences: Q3 Earnings Insights

Shares of Precision BioSciences DTIL remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share were down 21.95% year over year to ($0.50), which beat the estimate of ($0.66).

Revenue of $7,363,000 up by 51.35% from the same period last year, which beat the estimate of $3,620,000.

Looking Ahead

Precision BioSciences hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Technicals

Company's 52-week high was at $23.67

Company's 52-week low was at $4.46

Price action over last quarter: Up 18.02%

Company Description

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.